Seaford Pharmaceuticals Named Life Science Company of the Year at the 2026 LSO Awards
Seaford Pharmaceuticals Inc. is proud to announce that we have been awarded the 2026 Life Science Company of the Year by Life Sciences Ontario (LSO)—a recognition that celebrates our ongoing commitment to patient centred innovation, scientific excellence, and industry leadership.
Now in its 23rd year, the LSO Awards honour individuals and organizations whose contributions advance Ontario’s vibrant life sciences ecosystem. This year’s recipients represent leadership, discovery, and community impact across the sector, and Seaford is honoured to stand among them.
A Celebration of Innovation in Ontario
LSO’s 2026 awards showcase the depth of talent and innovation driving Ontario’s life sciences community forward. From groundbreaking research to commercialization success stories, this year’s honourees reflect the strength and diversity of the sector.
The 2026 award recipients include:
- Lifetime Achievement Award – John Wilkinson, President & CEO, Wilkinson Insight Incorporated
- Community Impact Award – Cate Murray, President & CEO, Stem Cell Network
- Leadership Award – Rafi Hofstein, Life Science Consultant, Boards Member & Mentor
- Life Science Company of the Year – Seaford Pharmaceuticals Inc.
- Emerging Company of the Year – AmacaThera Inc.
- Volunteer Awards – Kira Pejemsky and Adrian Kupesic (Bayer)
Honoured to Lead with Purpose
“From breakthrough innovation to sustained leadership and advocacy, this year’s recipients exemplify the excellence driving Ontario’s life sciences sector forward,” said Dr. Jason Field, President & CEO of Life Sciences Ontario.
Being selected as Life Science Company of the Year is a testament to Seaford’s ongoing dedication to delivering high‑quality pharmaceutical solutions that improve patient lives. We share this award with our team, partners, and healthcare community who make our work possible.
